Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash from Operations (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Cash from Operations for 16 consecutive years, with 30367000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 91.47% to 30367000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 185225000.0 through Dec 2025, up 189.34% year-over-year, with the annual reading at 185225000.0 for FY2025, 189.34% up from the prior year.
  • Cash from Operations hit 30367000.0 in Q4 2025 for Ani Pharmaceuticals, down from 44055000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 75812000.0 in Q2 2025 to a low of 18942000.0 in Q1 2022.
  • Historically, Cash from Operations has averaged 17016000.0 across 5 years, with a median of 17841500.0 in 2024.
  • Biggest five-year swings in Cash from Operations: plummeted 4865.15% in 2022 and later surged 1116.82% in 2023.
  • Year by year, Cash from Operations stood at 12185000.0 in 2021, then surged by 63.89% to 4400000.0 in 2022, then soared by 1116.82% to 44740000.0 in 2023, then crashed by 64.55% to 15860000.0 in 2024, then skyrocketed by 91.47% to 30367000.0 in 2025.
  • Business Quant data shows Cash from Operations for ANIP at 30367000.0 in Q4 2025, 44055000.0 in Q3 2025, and 75812000.0 in Q2 2025.